CEO Steve Rubakh Discloses $281K Stock Purchase, Now Owns ~50.8% of MedWellAI
MWAI sits 29% above its 52-week low of $0.2 on elevated volume (3.2× avg).
Summary
MedWellAI's CEO, Steve Rubakh, disclosed a $281,362.50 purchase of company stock at $0.61 per share, significantly increasing his stake to over 50% of the company, despite the transaction occurring in July 2025.
Key Events · Ownership and Investor Activity · MWAI
-
CEO Stock Purchase Disclosed
CEO Steve Rubakh reported acquiring 461,250 shares of common stock for $281,362.50.
-
Significant Insider Conviction
The purchase price of $0.61 per share is more than double the current market price, suggesting strong belief in the company's value at the time of the transaction.
-
Substantial Ownership Stake
This transaction increases the CEO's direct holdings to 3,323,451 shares, representing approximately 50.8% of the company's estimated outstanding shares.
-
Delayed Disclosure via Form 5
The transaction occurred on July 1, 2025, but was only recently disclosed on June 17, 2026, via a Form 5 filing, which is used for reporting previously unreported transactions.
Analysis · MWAI · Crypto Assets
CEO Steve Rubakh reported a significant purchase of 461,250 shares of MedWellAI common stock, valued at $281,362.50. This transaction, though dated July 2025, was only recently disclosed via a Form 5 filing. The purchase price of $0.61 per share is more than double the current stock price of $0.26, indicating strong conviction from the CEO at the time of the transaction. This purchase represents a substantial portion of the company's market capitalization and increases his direct ownership to 3,323,451 shares, which is approximately 50.8% of the company's estimated outstanding shares. This disclosure of a significant insider buy, even if delayed, can be a strong positive signal for investors, especially given the company's recent financial challenges noted in the May 10-Q.
At the time of this filing, MWAI was trading at $0.26 on OTC in the Crypto Assets sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $0.20 to $1.26. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.